# StreptomeDB


Update 2.0

Klementz D.; Döring K.; Lucas X.; Günther S.

Pharmaceutical Bioinformatics, Institute of Pharmaceutical Sciences, University of Freiburg - Germany dennis.klementz@pharmazie.uni-freiburg.de; kersten.doering@pharmazie.uni-freiburg.de

#### Overview

Streptomycetes became one of the most relevant genera for pharmaceutical research since 1943, when Albert Schatz isolated Streptomycin for the first time<sup>1</sup>. Nowadays, over 60% of all known antibiotics are produced by these bacteria<sup>2</sup>. An overwhelming amount of data concerning streptomycetes has been produced in the past 70 years, but it has never been offered in a centralized and freely-accessible database until the publication of the first version of StreptomeDB in January 2013<sup>2</sup>. Since that date, we could increase the initial size of our database by several hundred compounds. In addition, we have included several new features such as the integration of genomic and phylogenetic data, an advanced scaffold-based search system, and a comprehensive literature collection with specialized search options.



Albert Schatz [The Guardian magazin]

Pub Med


**All papers** 

"Inhouse"

software

### Compounds

StreptomeDB is the currently largest collection of natural compounds produced by streptomycetes, containing plenty of recently discovered structures, which cannot



be found in commonly used databases such as PubChem.

Additionally to the vast amount of curated data, we offer extensive background information for all included compounds such as chemical structures, predicted chemical properties, source organisms, and many more.

# Literature

We have collected information from a set of more than 18,000 full text articles concerning streptomycetes by text mining methods, which were integrated in our database. Additionally, we provide a multilayer search system, that enables an easy generation of personalized overviews and datasets, including advanced

> features such as relevance prediction, information about authors, publication year, or number of citations.


PubMed

Level 1 scaffold

Doxorubicin

**Streptome** 


Level 0 scaffold



## Genomics


We have integrated a comprehensive collection of genomic data for the strains contained in StreptomeDB. We included known gene clusters, all available full and draft genomes, and preprocessed and reviewed rRNA sequences.

We will also offer an interactive phylogenetic tree, which will e.g. allow the visualization of the frequency of a given scaffold in an evolutionary context.



### Scaffolds

Chemical scaffolds play a major role in computational high-throughout screening methods<sup>3</sup>, e.g. for drug discovery. With an advanced scaffold search system, we will offer the possibility to explore the chemical diversity of natural compounds produced by streptomycetes +0.



#### Conclusion

StreptomeDB comprises an extensive collection of data related to streptomycetes, with a focus on natural compounds. The presented upgrades will allow an advanced exploration of the chemical diversity of compounds produced by streptomycetes and a deeper understanding of their evolutionary background.







#### References:

- Schatz, A.; Bugle, E.; Waksman, S. A. Exp. Biol. Med. **1944**, 55, 66-69. Lucas, X.; Senger, C.; Erxleben, A.; Grüning, B. A.; Döring, K.; Mosch, J.;
- Flemming, S.; Günther, S. Nucleic Acids Res. 2013, D1130-D1136. Shelat, A.; Guy K. Nat. Chem. Biol. 2007, 3, 442-446